Loading...
Market
Story
Johnson & Johnson's Rybrevant Shows Positive Results, 49% Response Rate in Lung and Colorectal Cancer
Sep 14, 2024, 01:48 PM
Johnson & Johnson's RYBREVANT® (amivantamab-vmjw) in combination with chemotherapy has shown a positive overall survival trend compared to chemotherapy alone in patients with previously treated EGFR-mutated lung cancer. Additionally, the combination therapy demonstrated a 49 percent overall response rate in metastatic colorectal cancer. The Phase II data from Rybrevant in colorectal cancer suggest that bispecifics may outperform standard monoclonal antibodies, potentially ushering in curative potential. However, the Mariposa-2 combo was described as a 'toxic & expensive arrow' by a #ESMO24 discussant.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 20% • 25%
20%-40% • 25%
40%-60% • 25%
More than 60% • 25%
Less than 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
More than 60% • 25%
Below 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
Above 60% • 25%
Less than $2 billion • 25%
$2 billion to $3 billion • 25%
$3 billion to $4 billion • 25%
More than $4 billion • 25%
Lung cancer related indication • 25%
Other cancer indication • 25%
Non-cancer indication • 25%
No new approval • 25%